Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (<scp>CAPTIVATE</scp>)

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett A. English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart A. Turner,

Neurogastroenterology & Motility

Abstract

References